Share on StockTwits

HeartWare International (NASDAQ:HTWR) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Monday. They currently have a $95.10 price objective on the stock. Zacks‘s price objective indicates a potential upside of 17.26% from the stock’s previous close.

HTWR has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of HeartWare International in a research note on Friday, August 1st. They now have a $125.00 price target on the stock, down previously from $128.00. Analysts at Leerink Swann cut their price target on shares of HeartWare International from $120.00 to $105.00 in a research note on Friday, August 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. HeartWare International has an average rating of “Buy” and an average price target of $107.91.

HeartWare International (NASDAQ:HTWR) traded up 0.90% during mid-day trading on Monday, hitting $81.10. 115,874 shares of the company’s stock traded hands. HeartWare International has a 1-year low of $69.31 and a 1-year high of $105.84. The stock’s 50-day moving average is $84.15 and its 200-day moving average is $89.56. The company’s market cap is $1.379 billion.

HeartWare International (NASDAQ:HTWR) last released its earnings data on Thursday, July 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.45. The company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $67.01 million. On average, analysts predict that HeartWare International will post $-2.20 earnings per share for the current fiscal year.

In other HeartWare International news, Insider Jeffrey Larose sold 2,179 shares of HeartWare International stock on the open market in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $81.51, for a total value of $177,610.29. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.

To view Zacks’ full report, visit Zacks’ official website.

Receive News & Ratings for HeartWare International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.